Last €1.14 EUR
Change Today +0.032 / 2.90%
Volume 0.0
RYIN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 7:53 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for sunesis pharmaceuticals inc (RYIN)

Year over year, Sunesis Pharmaceuticals, Inc. has been able to grow revenues from $3.8M USD to $8.0M USD. Most impressively, the company has been able to reduce the percentage of sales devoted to selling, general and administrative costs from 244.41% to 136.22%. This was a driver that led to an improvement in the bottom line from a loss of $44.0M USD to a smaller loss of $34.6M USD.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Restated
Dec 31
2011
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues0.05.03.88.0
TOTAL REVENUES0.05.03.88.0
GROSS PROFIT0.05.03.88.0
Selling General & Admin Expenses, Total7.08.39.210.8
R&D Expenses14.422.629.228.9
OTHER OPERATING EXPENSES, TOTAL21.430.938.439.7
OPERATING INCOME-21.4-25.9-34.6-31.8
Interest Expense---0.3-1.9-2.9
NET INTEREST EXPENSE---0.3-1.9-2.9
Other Non-Operating Income (Expenses)-3.26.0-7.50.1
EBT, EXCLUDING UNUSUAL ITEMS-24.6-20.1-44.0-34.6
EBT, INCLUDING UNUSUAL ITEMS-24.6-20.1-44.0-34.6
Earnings from Continuing Operations-24.6-20.1-44.0-34.6
NET INCOME-24.6-20.1-44.0-34.6
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-24.6-20.1-44.0-34.6
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-24.6-20.1-44.0-34.6
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RYIN:GR €1.14 EUR +0.032

RYIN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NeurogesX Inc $0.0034 USD 0.00
POZEN Inc $8.29 USD +0.02
View Industry Companies
 

Industry Analysis

RYIN

Industry Average

Valuation RYIN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.4x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUNESIS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.